U21-S01. In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others
In vivo Efficacy Assays of drugs, nanomedicines, biomaterials and others
Preclinical studies for the evaluation of medical treatments, medical devices and surgical techniques in a controlled environment prior to their application in patients.
Conducting studies -both in human and veterinary medicine- of in vitro toxicity, in vivo toxicity, tolerance, pharmacodynamics, test product administration and procurement of non-clinical specimens, biocompatibility of medical devices, murine model embryo transfers, intracytoplasmic microinjection, oocyte vitrification, measurement and analysis of Natural Killer (NK) cell samples, seminogram and semen studies.
Creation of experimental animal models of various human diseases such as diabetes, obesity, hypercholesterolemia, hypertriglyceridemia, acute and chronic myocardial infarction, prostatic hyperplasia, ulcers, pleural adhesions, constrictive pericarditis and abdominal aortic aneurysm, among others. Possibility of working with a variety of animal species: rodents, rabbits, dogs, cats, pigs and sheep.
Application of experimental animal models for research in several longitudinal areas such as cardiovascular, hepatic and digestive, respiratory and systemic diseases, endocrinology and urology, gynecological and reproductive diseases, prostheses, among others.
Customer benefits
Preclinical studies can be carried out under good laboratory practice (GLP 23.05/001 AEMPS), optimal for reporting to the AEMPS, EMA and FDA.
In vivo toxicity, tolerance, pharmacodynamics, test product administration and non-clinical specimen collection and biocompatibility studies of medical devices are carried out according to OECD decision C(89)87.
Registered facilities for the use and breeding of experimental animals, which has an Animal Welfare Ethics Committee and a pharmacy and formulation laboratory.
Target customer
Entities involved in the research, development or commercialization of medical devices or treatments such as pharmaceutical and biotechnology companies, academic and scientific researchers, medical device companies, research institutions and laboratories, and governmental and regulatory organizations.
Additional information
- Jiménez-Holguín J, Lozano D, Saiz-Pardo M, de Pablo D, Ortega L, Enciso S, Fernández-Tomé B, Díaz-Güemes I, Sánchez-Margallo FM, Portolés MT, Arcos D. Osteogenic-angiogenic coupled response of cobalt-containing mesoporous bioactive glasses in vivo. Acta Biomater. 2024 Mar 1;176:445-457. doi: 10.1016/j.actbio.2024.01.003. Epub 2024 Jan 6. PMID: 38190928.
- Lucas-Cava V, Sánchez-Margallo FM, Moreno-Lobato B, Dávila-Gómez L, Lima-Rodríguez JR, García-Martínez V, López-Sánchez C, Sun F. Prostatic artery occlusion: initial findings on pathophysiological response in a canine prostate model. Transl Androl Urol. 2022 Dec;11(12):1655-1666. doi: 10.21037/tau-22-423. PMID: 36632152; PMCID: PMC9827397.
- Arcos D, Gómez-Cerezo N, Saiz-Pardo M, de Pablo D, Ortega L, Enciso S, Fernández-Tomé B, Díaz-Güemes I, Sánchez-Margallo FM, Casarrubios L, Feito MJ, Portolés MT, Vallet-Regí M. Injectable mesoporous bioactive nanoparticles regenerate bone tissue under osteoporosis conditions. Acta Biomater. 2022 Oct 1;151:501-511. doi: 10.1016/j.actbio.2022.07.067. Epub 2022 Aug 3. PMID: 35933104.
- Soria F, de La Cruz JE, Caballero-Romeu JP, Pamplona M, Pérez-Fentes D, Resel-Folskerma L, Sanchez-Margallo FM. Comparative assessment of biodegradable-antireflux heparine coated ureteral stent: animal model study. BMC Urol. 2021 Feb 28;21(1):32. doi: 10.1186/s12894-021-00802-x. PMID: 33639905; PMCID: PMC7916282.
- Marinaro F, Casado JG, Blázquez R, Brun MV, Marcos R, Santos M, Duque FJ, López E, Álvarez V, Usón A, Sánchez-Margallo FM. Laparoscopy for the Treatment of Congenital Hernia: Use of Surgical Meshes and Mesenchymal Stem Cells in a Clinically Relevant Animal Model. Front Pharmacol. 2020 Sep 25;11:01332. doi: 10.3389/fphar.2020.01332. PMID: 33101010; PMCID: PMC7546355.